1
|
Xu W, Zhang ZY, Sun D, Yan YX, Zhang Y, Li SM, Chen ZY. Effects of mind-regulating acupuncture on pain, negative emotion and sleep quality in patients with postherpetic neuralgia: a randomized controlled pilot trial. Zhen Ci Yan Jiu 2024; 49:499-505. [PMID: 38764121 DOI: 10.13702/j.1000-0607.20230195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2024]
Abstract
OBJECTIVES To observe the effect of mind-regulating acupuncture on pain intensity, sleep quality, negative emotion in patients with postherpetic neuralgia (PHN), and evaluate the clinical effect of mind-regulating acupuncture combined with surrounding needling and heavy moxibustion at Ashi points (Extra) in treatment of PHN. METHODS The patients with PHN were randomly divided into a control group (35 cases, 2 cases dropped out) and a comprehensive therapy group (35 cases). The patients in the control group were treated with surrounding needling and heavy moxibustion at Ashi points. In the comprehensive therapy group, the mind-regulating acupuncture therapy was delivered besides the treatment as the control group. The treatment was given once daily, one course of treatment was composed of 6 days and 2 courses were required in the 2 groups. Before and after treatment, the pain conditions were assessed using pain rating index (PRI), visual analogue scale (VAS) and present pain intensity (PPI), the negative emotions were assessed using Hamilton anxiety scale (HAMA) and Hamilton depression scale (HAMD), and the sleep quality with Pittsburgh sleep quality index (PSQI). One week before and one week after treatment, the average sleep time was recorded. The therapeutic effect of 2 groups was evaluated. The effective cases of 2 groups were followed up in 2 months after treatment completion and the recurrence of neuralgia was recorded. RESULTS There were no statistical differences in the above indicators between the 2 groups before treatment. After 2 courses of treatment, the scores of PRI, VAS, PPI, HAMA, HAMD and PSQI were reduced when compared with those before treatment in the patients of the 2 groups (P<0.05), and the average sleep time was increased (P<0.05). The scores of PRI, VAS, PPI, HAMA, HAMD and PSQI in the comprehensive therapy group, as well as the average sleep time were all improved when compared with those of the control group (P<0.05). The total effective rate in the comprehensive therapy group (34/35, 97.14%) was higher than that of the control group (27/33, 81.82%, P<0.05) and the recurrence rate was lower ([2/34, 5.88%]vs[8/27, 29.63%], P<0.05). CONCLUSIONS The combination of mind-regulating acupuncture with surrounding needling and heavy moxibustion at Ashi acupoint can effectively relieve PHN. Compared with the traditional surrounding acupuncture in pain area combined with moxibustion at Ashi points, this comprehensive therapy is more effective for ameliorating pain intensity, improving sleep quality and reducing negative emotions. It is also effective for declining the recurrence.
Collapse
Affiliation(s)
- Wei Xu
- 1Department of Rehabilitation Medicine, Department of Neurosurgery, (, The Third People's Hospital of Hangzhou, Hangzhou 310009, China)
| | - Zu-Yong Zhang
- 1Department of Rehabilitation Medicine, Department of Neurology, The Third People's Hospital of Hangzhou, Hangzhou 310009, China), (, The Third People's Hospital of Hangzhou, Hangzhou 310009, China.
| | - Dan Sun
- 1Department of Rehabilitation Medicine, Department of Neurosurgery, (, The Third People's Hospital of Hangzhou, Hangzhou 310009, China)
| | | | | | - Shi-Min Li
- 1Department of Rehabilitation Medicine, Department of Neurosurgery, (, The Third People's Hospital of Hangzhou, Hangzhou 310009, China)
| | - Zhou-Yang Chen
- 1Department of Rehabilitation Medicine, Department of Neurosurgery, (, The Third People's Hospital of Hangzhou, Hangzhou 310009, China)
| |
Collapse
|
6
|
Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010; 182:1731-6. [PMID: 20921251 PMCID: PMC2972323 DOI: 10.1503/cmaj.091711] [Citation(s) in RCA: 188] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Vaccination against herpes zoster is being considered in many countries. We conducted a multicentre prospective study to describe the impact of herpes zoster and postherpetic neuralgia on health-related quality of life. METHODS From October 2005 to July 2006, 261 outpatients aged 50 years or older with herpes zoster were recruited from the clinical practices of 83 physicians within 14 days after rash onset. The Zoster Brief Pain Inventory was used to measure severity of pain and interference with activities of daily living because of pain. The EuroQol EQ-5D assessment tool was used to measure quality of life. These outcomes were assessed at recruitment and on days 7, 14, 21, 30, 60, 90, 120, 150 and 180 following recruitment. RESULTS Acute herpes zoster interfered in all health domains, especially sleep (64% of participants), enjoyment of life (58%) and general activities (53%). The median duration of pain was 32.5 days. The median duration of interference with activities of daily living because of pain varied between 27 and 30 days. Overall, 24% of the participants had postherpetic neuralgia (pain for more than 90 days after rash onset). Anxiety and depression, enjoyment of life, mood and sleep were most frequently affected during the postherpetic neuralgia period. The mean EQ-5D score was 0.59 at enrolment and remained at 0.67 at all follow-up points among participants who reported clinically significant pain. INTERPRETATION These data support the need for preventive strategies and additional early intervention to reduce the burden of herpes zoster and postherpetic neuralgia.
Collapse
Affiliation(s)
- Mélanie Drolet
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - Marc Brisson
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - Kenneth E. Schmader
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - Myron J. Levin
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - Robert Johnson
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - Michael N. Oxman
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - David Patrick
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - Caty Blanchette
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| | - James A. Mansi
- From the Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec (Drolet, Brisson, Blanchette), Québec, Que.; the Département de médecine sociale et préventive, Université Laval (Drolet, Brisson), Québec, Que.; the Center for the Study of Aging and Human Development, Division of Geriatrics, Department of Medicine, Duke University Medical Center, and the Geriatric Research, Education and Clinical Center, Durham VA Medical Center (Schmader), Durham, USA; the Department of Pediatrics and Medicine, University of Colorado, Denver, and the Health Sciences Center (Levin), Aurora, USA; the University of Bristol and Bristol Royal Infirmary (Johnson), Bristol, UK; the Department of Medicine and Pathology, University of California at San Diego and the San Diego VA Medical Center (Oxman), La Jolla, USA; and the Department of Medicine, University of British Columbia, and the BC Centre for Disease Control (Patrick), Vancouver, BC. James Mansi was an employee of Merck Frosst Canada Ltd. (Scientific Affairs) during protocol development, study execution, data analysis and manuscript submission; he is currently an employee of Novartis Pharmaceuticals Canada Inc. (Novartis Vaccines & Diagnostics)
| |
Collapse
|